Cargando…
EZH2 and CD79B mutational status over time in B-cell non-Hodgkin lymphomas detected by high-throughput sequencing using minimal samples
BACKGROUND: Numerous genomic abnormalities in B-cell non-Hodgkin lymphomas (NHLs) have been revealed by novel high-throughput technologies, including recurrent mutations in EZH2 (enhancer of zeste homolog 2) and CD79B (B cell antigen receptor complex-associated protein beta chain) genes. This study...
Autores principales: | Saieg, Mauro Ajaj, Geddie, William R, Boerner, Scott L, Bailey, Denis, Crump, Michael, da Cunha Santos, Gilda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799012/ https://www.ncbi.nlm.nih.gov/pubmed/23361872 http://dx.doi.org/10.1002/cncy.21262 |
Ejemplares similares
-
Preanalytic parameters in epidermal growth factor receptor mutation testing for non–small cell lung carcinoma: A review of cytologic series
por: da Cunha Santos, Gilda, et al.
Publicado: (2015) -
Diagnosis of B-Cell Non-Hodgkin Lymphomas with Small-/Intermediate-Sized Cells in Cytopathology
por: Schwock, Joerg, et al.
Publicado: (2012) -
Clinicopathological significance of CD79a expression in classic Hodgkin lymphoma
por: Sakatani, Akio, et al.
Publicado: (2020) -
Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with EZH2 mutation in Japan
por: Izutsu, Koji, et al.
Publicado: (2021) -
Immunogenicity of recurrent mutations in MYD88 and EZH2 in non-Hodgkin lymphomas
por: Nielsen, Julie S, et al.
Publicado: (2015)